FrancophonIA/ELRC3.0 huggingface dataset:
English: Episalvan gel was shown to reduce wound healing times.
Estonian: Episalvan geel lühendab haava paranemise kestust.
English: For practical information about using Episalvan, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Episalvani kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: It is thought that the active substance in Episalvan, birch bark extract, helps the cells that make up the outer layer of the skin (keratinocytes) grow and move quickly towards the gap created by the wound, therefore helping wounds to heal faster.
Estonian: Arvatakse, et Episalvani toimeaine kasetohuekstrakt aitab naha välimist kihti moodustavatel rakkudel (keratinotsüüdid) kasvada ja kiiresti haavakanali suunas migreeruda, võimaldades haavadel kiiremini paraneda.
English: In the first study, the average time from surgery to wound closure was 17.1 days for the wounds treated with standard wound dressing only and 15.5 days for the wounds also treated with Episalvan.
Estonian: Esimese uuringu põhjal oli keskmine aeg kirurgilisest sekkumisest kuni haava sulgumiseni 17,1 päeva, kui kasutati vaid tavapärast haavasidumist, ja 15,5 päeva, kui haavale kanti lisaks ka Episalvanit.
English: These are wounds where the upper layers of the skin have been lost, for example by a burn or during surgical skin grafting.
Estonian: Pindmiste haavade korral on hävinud naha pealmised kihid, näiteks põletuse või kirurgilise nahatransplantaadi võtmise korral.
English: Episalvan is a medicine used in adults to treat partial-thickness skin wounds.
Estonian: Episalvanit kasutatakse pindmiste nahahaavade ravimiseks täiskasvanutel.
English: For more information about treatment with Episalvan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Episalvaniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: A third study involved 57 patients with partial-thickness burn wounds who had half their wound treated with Episalvan and the other half with a standard disinfectant gel.
Estonian: Kolmandas uuringus, milles osales 57 pindmiste põletushaavadega patsienti, raviti haava ühte poolt Episalvaniga ja teist tavapärase desinfitseeriva geeliga.
English: How is Episalvan used?
Estonian: Kuidas Episalvanit kasutatakse?
English: Both wound halves were also covered with a wound dressing.
Estonian: Haava mõlemale poolele asetati ka side.
English: Episalvan is available as a gel that should be applied as a thin layer (1 mm in thickness) to the wound, which should then be covered by a wound dressing.
Estonian: Episalvanit turustatakse geelina, mida tuleb kanda õhukese kihina (paksus 1 mm) haavale ja haava seejärel siduda.
English: How does Episalvan work?
Estonian: Kuidas Episalvan toimib?
English: What benefits of Episalvan have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Episalvani kasulikkus?
English: The patients received Episalvan together with wound dressing on one half of the wound, while the other half of the wound was treated with standard wound dressing only.
Estonian: Patsientide haava ühele poolele asetati side koos Episalvaniga ja haava teisele poolele asetati ainult side.
English: Episalvan contains a dry extract from birch bark.
Estonian: Episalvan sisaldab kasetohust tehtud kuivekstrakti.
English: Episalvan birch bark extract
Estonian: Episalvan kasetohuekstrakt
English: What is Fulphila?
Estonian: Mis on Fulphila?
English: Withdrawal of the marketing authorisation application for Fulphila (pegfilgrastim) EMA/577551/2017
Estonian: Müügiloa taotluse tagasivõtmise teave: Fulphila (pegfilgrastiim) EMA/577551/2017
English: Other concerns related to the description of the manufacturing process, the control of impurities in the active substance and the sterilisation of the final product.
Estonian: Muud probleemid olid seotud tootmisprotsessi kirjelduse, toimeaine lisandisisalduse reguleerimise ja lõpptoote steriliseerimisega.
English: Neutropenia is a side effect of certain cancer treatments and can lead to development of serious infections.
Estonian: Neutropeenia on teatud vähiravimite kõrvalnäht ning võib põhjustada raskeid infektsioone.
English: Withdrawal of the marketing authorisation application for Fulphila (pegfilgrastim)
Estonian: Müügiloa taotluse tagasivõtmise teave: Fulphila (pegfilgrastiim)
English: Fulphila is a medicine that contains the active substance pegfilgrastim.
Estonian: Fulphila on ravim, mis sisaldab toimeainena pegfilgrastiimi.
English: The company presented results of studies designed to show that Fulphila is highly similar to its reference medicine Neulasta in terms of chemical structure, purity, the way it works and how the body handles the medicine.
Estonian: Ettevõte esitas tulemused uuringutest, mille eesmärk oli tõendada, et Fulphila sarnaneb keemilise struktuuri, puhtuse, toimemehhanismi ja organismis metaboliseerumise poolest võrdlusravimiga Neulasta.
English: This means that Fulphila was intended to be highly similar to a biological medicine already authorised in the European Union (the ‘reference medicine') called Neulasta.
Estonian: See tähendab, et Fulphila pidi olema sarnane bioloogilise ravimiga (võrdlusravimiga) Neulasta, millel juba on Euroopa Liidus müügiluba.
English: It encourages the bone marrow to produce more neutrophils and improves the patient's ability to fight off infections.
Estonian: See soodustab neutrofiilide teket luuüdis ja suurendab patsiendi vastupanuvõimet infektsioonidele.
English: Because filgrastim is pegylated, its removal from the body is slowed down, allowing the medicine to be given less often.
Estonian: Et filgrastiim on pegüleeritud, püsib see organismis kauem ja ravimit saab manustada harvem.
English: One of the CHMP's main concerns was the lack of a certificate of Good Manufacturing Practice (GMP) for the manufacturing site of the product.
Estonian: Üks komitee väljendatud põhiprobleeme oli, et ravimi tootmiskohal puudus hea tootmistava sertifikaat.
English: Fulphila was to be used in cancer patients to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell that fights infection) and the occurrence of febrile neutropenia (neutropenia with fever).
Estonian: Fulphilat kavatseti kasutada vähipatsientidel, et vähendada neutropeenia kestust (neutropeenia on neutrofiilide ehk teatud infektsioonivastaste valgeliblede vähesus) ja febriilse (palavikuga) neutropeenia esinemissagedust.
English: In addition, one study in 194 patients receiving cancer medicines compared the safety, effectiveness and immunogenicity, meaning the medicine's ability to trigger the production of antibodies, of Fulphila and Neulasta.
Estonian: Peale selle võrreldi ühes 194 vähiravipatsiendi uuringus Fulphila ja Neulasta ohutust, efektiivsust ja immunogeensust (ravimi võimet stimuleerida antikehade teket).
English: In its letter notifying the Agency of the withdrawal of the application, the company stated that it was withdrawing the application because a GMP certificate for the manufacturing site of Fulphila could not be obtained in the time available.
Estonian: Ettevõtte kirjas, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, märgib ettevõte, et võtab taotluse tagasi, sest ta ei suutnud ettenähtud aja jooksul hankida Fulphila tootmiskoha jaoks hea tootmistava sertifikaati.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the quality of Fulphila had not been demonstrated.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et ravimi Fulphila kvaliteet ei ole tõendatud.
English: Fulphila was developed as a ‘biosimilar' medicine.
Estonian: Fulphila töötati välja bioloogiliselt sarnase ravimina.
English: Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Fulphila could not have been approved to reduce neutropenia in patients taking cancer treatments.
Estonian: Tuginedes esitatud andmete analüüsile, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et ravimi Fulphila kasutamist neutropeenia vähendamiseks vähiravi saavatel patsientidel ei ole võimalik heaks kiita.
English: The company informed the CHMP that the withdrawal does not impact ongoing clinical trials with Fulphila.
Estonian: Ettevõte teatas inimravimite komiteele, et taotluse tagasivõtmine ei mõjuta praegu Fulphila kliinilistes uuringutes osalevaid patsiente.
English: The active substance in Fulphila and Neulasta, pegfilgrastim, consists of filgrastim that has been 'pegylated' (attached to a chemical called polyethylene glycol).
Estonian: Fulphila ja Neulasta toimeaine pegfilgrastiim koosneb pegüleeritud (polüetüleenglükooliga (PEG) kaetud) filgrastiimist.
English: protein called granulocyte-colony-stimulating factor (G-CSF).
Estonian: Filgrastiim on väga sarnane teatud inimvalguga, granülotsüütide kolooniat stimuleeriva faktoriga (G-CSF).
English: What was Fulphila expected to be used for?
Estonian: Milleks kavatseti Fulphilat kasutada?
English: officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Fulphila, for reducing neutropenia in patients taking cancer treatments.
Estonian: teatas 3. augustil 2017 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Fulphila müügiloa taotlus.
English: 1 vial +1 infusion bag +1 syringe +1 vial adaptor
Estonian: 1 viaal + infusioonikott + 1 süstal + 1 viaali adapter
English: Powder : 200mg Solvent: 20 ml (10 mg/ml)
Estonian: Pulber: 200 mg Lahusti: 20 ml (10 mg/ml)
English: Intravenous use Powder: vial (glass) Solvent: infusion bag
Estonian: Pulber: klaasviaal Lahusti: infusioonikott
English: Powder for solution for infusion
Estonian: 200 mg Infusioonilahuse pulber
English: Powder and solvent for solution for infusion
Estonian: 200 mg Infusioonilahuse pulber ja lahust
English: They should be taken within one hour after morning and evening meals.
Estonian: Neid tuleb võtta ühe tunni jooksul pärast hommiku- ja õhtusööki.
English: Colorectal cancer
Estonian: Kolorektaalvähk
English: Lonsurf received a marketing authorisation valid throughout the European Union on 25 April 2016.
Estonian: Lonsurf on saanud müügiloa, mis kehtib kogu ELis, 25. aprillil 2016.
English: What measures are being taken to ensure the safe and effective use of Lonsurf?
Estonian: Mis meetmed võetakse, et tagada Lonsurfi ohutu ja efektiivne kasutamine?
English: Other information about Lonsurf
Estonian: Muu teave Lonsurfi kohta
English: The tablets are taken twice a day on certain days of each treatment cycle.
Estonian: Tablette võetakse iga ravitsükli teatud päevadel kaks korda ööpäevas.
English: The European Medicines Agency decided that Lonsurf's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Lonsurfi kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Lonsurf is available as tablets (15 mg trifluridine and 6.14 mg tipiracil; 20 mg trifluridine and 8.19 mg tipiracil) and is given in treatment cycles of 28 days.
Estonian: Lonsurfi turustatakse tablettidena (15 mg trifluridiini ja 6,14 mg tipiratsiili; 20 mg trifluridiini ja 8,19 mg tipiratsiili) ja manustatakse 28-päevaste ravitsüklitena.
English: All patients had previously received other treatments.
Estonian: Kõiki patsiente olid varem ravitud vähemalt kahe muu ravimeetodiga.
English: What is Lonsurf and what is it used for?
Estonian: Mis on Lonsurf ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Lonsurf are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Lonsurfi kasutamise kohta pidevat järelevalvet.
English: Further information on Lonsurf can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/lonsurf.
Estonian: Lisateave Lonsurfi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/lonsurf Kokkuvõtte viimane uuendus: 09.2019
English: Why is Lonsurf authorised in the EU?
Estonian: Miks Lonsurf ELis heaks kiideti?
English: This reduces the growth of cancer cells, while normal cells are only slightly affected.
Estonian: See vähendab vähirakkude kasvu, kuid normaalsed rakud kahjustuvad vähe.
English: Tipiracil increases the level of trifluridine in the blood by slowing its breakdown.
Estonian: Tipiratsiil suurendab trifluridiini sisaldust veres, aeglustades selle lagunemist.
English: Lonsurf (trifluridine / tipiracil)
Estonian: Lonsurf (trifluridiin/tipiratsiil)
English: This therefore boosts trifluridine's effect.
Estonian: Seega võimendab see trifluridiini toimet.
English: All patients received supportive care.
Estonian: Kõik uuringus osalenud patsiendid said toetavat ravi.
English: The Agency considered that the measures put in place are adequate to manage these risks.
Estonian: Inimravimite komitee tunnistas nende riskide ohjamiseks võetud meetmed asjakohaseks ja piisavaks.
English: Treatment with Lonsurf should continue for as long as benefits can be seen and the side effects are tolerable.
Estonian: Ravi Lonsurfiga tuleb jätkata seni, kuni täheldatakse selle kasulikkust ja kõrvalnähud on talutavad.
English: Side effects reported with Lonsurf are carefully evaluated and any necessary action taken to protect patients.
Estonian: Lonsurfi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: It is used when the cancer is metastatic (has spread to other parts of the body) in patients who have already been treated with, or who cannot be given, other treatments for their cancer.
Estonian: Seda kasutatakse, kui vähk on metastaatiline (levinud organismis ka mujale) patsientidel, kes on juba saanud vähiravi muude ravimeetoditega või kellele need ei sobi.
English: For more information about using Lonsurf, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Lonsurfi kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lonsurf have been included in the summary of product characteristics and the package leaflet.
Estonian: Lonsurfi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Lonsurf is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells).
Estonian: Lonsurf on tsütotoksiline ravim (ravim, mis hävitab jagunevaid rakke, näiteks vähirakke).
English: Treatment with Lonsurf should be prescribed by a doctor who is experienced in the use of cancer medicines.
Estonian: Ravi Lonsurfiga peab määrama vähiravimite kasutamises kogenud arst.
English: In the body, trifluridine is converted into an active form that is incorporated into DNA, the genetic material of cells.
Estonian: Trifluridiin muundub organismis aine aktiivseks vormiks, mis kaasatakse rakkude geneetilisse materjali DNA-sse.
English: What are the risks associated with Lonsurf?
Estonian: Mis riskid Lonsurfiga kaasnevad?
English: The most common side effects with Lonsurf (which may affect more than 3 in 10 people) are neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), feeling sick, tiredness and anaemia (low red blood cell counts).
Estonian: Lonsurfi kõige sagedamad kõrvalnähud (võivad esineda enam kui 3 patsiendil 10st) on neutropeenia (neutrofiilide ehk teatud infektsioonivastaste valgeliblede vähesus), iiveldus, väsimus ja aneemia (erütrotsüütide ehk vere punaliblede vähesus).
English: The conversion of trifluridine into its active form occurs more readily in cancer cells than in normal cells, leading to higher levels of the active form of the medicine and a longer duration of action in cancer cells.
Estonian: Trifluridiin muundub aktiivseks vormiks kergemini vähirakkudes kui normaalsetes rakkudes, mistõttu ravimi aktiivse vormi sisaldus on vähirakkudes suurem ja püsib neis kauem.
English: As a result, trifluridine interferes with DNA function and prevents the cells from dividing to make more cells.
Estonian: Selle tulemusena häirib trifluridiin DNA funktsiooni ja takistab rakkude jagunemist ja paljunemist.
English: Regarding its safety, although Lonsurf's side effects can be serious they are in line with what can be expected for this type of medicine.
Estonian: Ehkki ohutuse seisukohalt võivad Lonsurfi kõrvalnähud olla rasked, on need kooskõlas tsütotoksilise ravimi eeldatavate kõrvalnähtudega.
English: How does Lonsurf work?
Estonian: Kuidas Lonsurf toimib?
English: In a study involving 507 adults with metastatic gastric cancer, patients treated with Lonsurf lived on average for 5.7 months compared with 3.6 months for patients who received placebo.
Estonian: Metastaatilise maovähiga 507 täiskasvanu uuringus elasid Lonsurfiga ravitud patsiendid keskmiselt 5,7 kuud ja platseebot saanud patsiendid 3,6 kuud.
English: For the full list of side effects and restrictions of Lonsurf, see the package leaflet.
Estonian: Lonsurfi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: It contains two active substances: trifluridine and tipiracil.
Estonian: See sisaldab kaht toimeainet, trifluridiini ja tipiratsiili.
English: How is Lonsurf used?
Estonian: Kuidas Lonsurfi kasutatakse?
English: In one main study involving 800 patients, those treated with Lonsurf lived on average for 7.1 months compared with 5.3 months for patients who were treated with placebo (a dummy treatment).
Estonian: Ühes 800 patsiendi põhiuuringus elasid Lonsurfiga ravitud patsiendid keskmiselt 7,1 kuud ning platseebot (näiv ravim) saanud patsiendid 5,3 kuud.
English: The most serious side effects are bone marrow suppression (when the bone marrow produces fewer blood cells than normal) and effects on the gut (diarrhoea and feeling sick).
Estonian: Kõige raskemad kõrvalnähud on luuüdi supressioon (luuüdis tekib normaalsest vähem vererakke) ja soolele avalduvad toimed (kõhulahtisus ja iiveldus).
English: The Agency considered that the benefit of Lonsurf in prolonging survival in patients with metastatic colorectal and metastatic gastric cancer who have received previous treatment was important.
Estonian: Amet märkis, et Lonsurfi kasulikkus varem ravitud metastaatilise kolorektaalvähiga ja metastaatilise maovähiga patsientide elumuse pikendamisel on oluline.
English: Lonsurf contains the active substances trifluridine and tipiracil.
Estonian: Lonsurf sisaldab toimeainetena trifluridiini ja tipiratsiili.
English: The doctor may reduce the dose or interrupt treatment if certain side effects develop.
Estonian: Teatud kõrvalnähtude ilmnemisel võib arst annust vähendada või ravi katkestada.
English: Lonsurf is a medicine used to treat adults with colorectal cancer (cancer of the large bowel) and gastric (stomach) cancer.
Estonian: Lonsurf on ravim, mida kasutatakse kolorektaalvähi (jämesoolevähi) ja maovähi raviks täiskasvanutel.
English: What benefits of Lonsurf have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Lonsurfi kasulikkus?
English: Gastric cancer
Estonian: Maovähk
English: An overview of Lonsurf and why it is authorised
Estonian: Ülevaade ravimist Lonsurf ja ELis müügiloa väljastamise põhjendus
English: Lonsurf prolonged overall survival of patients with metastatic colorectal cancer and in patients with metastatic gastric cancer.
Estonian: Lonsurf pikendas varem muud ravi saanud metastaatilise kolorektaalvähiga patsientide üldist elumust.
English: The medicine can only be obtained with a prescription.
Estonian: Lonsurf on retseptiravim.
English: It usually occurs in one part of the body and can last for several weeks.
Estonian: Tavaliselt tekib see ühes kehapiirkonnas ja kestab mitu nädalat.
English: Average VE§
Estonian: Keskmine VE§
English: • if you have a fever
Estonian: • kui teil on palavik
English: - This vaccine has been prescribed for you only.
Estonian: - See vaktsiin on välja kirjutatud üksnes teile.
English: • if you have or have had any medical problems or any allergies
Estonian: • kui teil on või on olnud ükskõik milliseid meditsiinilisi probleeme või allergiaid
English: e. Other studies
Estonian: e. Teised uuringud
English: North Carolina 27712 U.S.A
Estonian: North Carolina 27712
English: VE over study period‡
Estonian: VE kogu uuringuperioodi jooksul‡
English: It may lead to severe and long-lasting pain and scarring.
Estonian: See võib tekitada tugevat ja pikaajalist valu ning löövet.
English: Sometimes, after many years, the virus becomes active again and causes shingles.
Estonian: Mõnikord pärast mitmeid aastaid muutub viirus taas aktiivseks ja põhjustab vöötohatist.
English: • if you have been told by your doctor that you have a weakened immune system as a result of a disease, medicines, or other treatment
Estonian: • kui teie arst on teile öelnud, et teil on nõrgenenud immuunsüsteem haiguse, ravimite või mõne teise ravi tõttu;
English: After the shingles blisters heal, pain can last for months or years and may be severe.
Estonian: Pärast vöötohatisevillide paranemist võib valu kesta kuid ja aastaid ning olla tugev.
English: The safety and efficacy of ZOSTAVAX in children and adolescents have not been established.
Estonian: ZOSTAVAXi ohutust ja efektiivsust ei ole lastel ja noorukitel kindlaks tehtud.
English: • if you have a blood disorder or any type of cancer that weakens your immune system
Estonian: • kui teil on verehaigus või mis tahes tüüpi vähk, mis nõrgestab immuunsüsteemi;
English: See sections 4.3 and 4.4.
Estonian: Vaata lõigud 4.3 ja 4.4.
English: Rarely (may affect up to 1 in 1,000 people), allergic reactions may occur.
Estonian: Harva (võib tekkida kuni 1 inimesel 1000-st) võivad tekkida allergilised reaktsioonid.
English: Other medicines and ZOSTAVAX
Estonian: Muud ravimid ja ZOSTAVAX
English: VZV-seronegative adults
Estonian: VZV-seronegatiivsed täiskasvanud
English: The two vaccines should be given as separate injections at different body sites.
Estonian: Kaks vaktsiini tuleb manustada eraldi süstidena erinevatesse kehapiirkondadesse.
English: If you have an allergic reaction, call your doctor right away.
Estonian: Kui teil tekib allergiline reaktsioon, võtke kohe ühendust oma arstiga.
English: Date of first authorisation: 19 May 2006 Date of latest renewal: 11 February 2016
Estonian: Müügiloa esmase väljastamise kuupäev: 19/05/2006 Müügiloa viimase uuendamise kuupäev: 11/02/2016
English: It is important to use a separate sterile syringe and needle for each patient to prevent transmission of infectious agents from one individual to another.
Estonian: Oluline on kasutada iga patsiendi jaoks eraldi steriilset süstalt ja nõela, et vältida nakkustekitajate ülekandumist ühelt isikult teisele.
English: • if you have HIV infection
Estonian: • kui teil on HIV-nakkus
English: This vaccine may contain traces of neomycin.
Estonian: See vaktsiin võib sisaldada jälgi neomütsiinist.
English: As these events are reported voluntarily from a population of uncertain size, it is not possible to reliably calculate their frequency or establish a causal relationship to vaccine exposure.
Estonian: Kuna nendest kõrvaltoimetest on teatatud vabatahtlikult määramatu suurusega populatsioonist, siis ei ole alati võimalik usaldusväärselt hinnata nende esinemissagedust ega põhjuslikku seost vaktsiini kasutamisega.
English: A decision must be made whether to discontinue breast-feeding or to not administer ZOSTAVAX taking into account the benefit of breast-feeding for the child and the benefit of vaccination for the woman.
Estonian: Rinnaga toitmise katkestamine või ZOSTAVAXi mittemanustamine tuleb otsustada, arvestades imetamise kasu lapsele ja vaktsineerimise kasu naisele.
English: • Active untreated tuberculosis.
Estonian: • Aktiivne ravimata tuberkuloos.